Articles · Sexual Health

Sexual Desire in Menopause

Why desire drops in midlife and which interventions actually work.

6 min read · Published May 30, 2026 · Updated August 28, 2026

Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.

Sexual Desire in Menopause

Reduced sexual desire is one of the most common sexual health concerns women report in perimenopause and postmenopause, and one of the least discussed in clinical settings. Treatments often fail because they are aimed at a problem with several causes as though it had just one.

Low desire in midlife is not simply a hormone deficiency to correct, though hormonal factors are real and relevant. It is a mix of physical changes, psychological shifts, relationship dynamics, and sleep disruption, and each of those responds to a different intervention.

The Physical Drivers

Genitourinary syndrome of menopause (GSM). The most commonly overlooked physical driver of reduced desire is pain. Estrogen withdrawal thins and dries vaginal tissue and reduces its elasticity, which causes pain during penetrative sex. Pain during sex is a learned deterrent. The brain and body do not seek out experiences that are reliably uncomfortable, and worry about pain reduces desire before any physical contact.

Research consistently finds that when painful sex from GSM is treated effectively (with local vaginal estrogen, vaginal moisturizers, or ospemifene), sexual desire often recovers on its own.[1] The desire problem was never hormonal in the usual sense. It was a rational response to pain. This is the most important physical driver to assess and treat first.

Sleep deprivation. Chronic broken sleep, common in perimenopause, reduces libido through several pathways: lower testosterone (poor sleep reduces gonadotropin secretion and testosterone production), higher cortisol (which suppresses sex hormone production), and a general drop in the capacity for positive emotion and reward-seeking. Persistent exhaustion deprioritizes non-essential reward-seeking in response to an energy deficit. Libido is not broken, it is rationed.

Depression and anxiety. Mood disorders are significantly more common during perimenopause. Both depression and anxiety directly suppress sexual desire. Anhedonia (loss of the capacity to feel pleasure) is a core feature of depression that includes, but is not limited to, sexual desire. Treating the mood disorder often partly or fully restores sexual interest.

The Relational Drivers

A 2024 systematic review of women’s experiences of sexuality during the menopausal transition found that relationship factors are central to the desire story at this life stage.[2] Several patterns came up consistently.

Partner dynamics. When resentment, poor communication, or reduced emotional closeness runs through a relationship, testosterone therapy does not restore desire. Sexual desire in women is more context-dependent and relationship-responsive than in men, and no medication compensates for a relational environment that does not support it.

Body image and identity shifts. The physical changes of midlife (weight redistribution, skin changes, altered energy) change how women see themselves sexually. Women describe feeling less desirable, less at home in their bodies, and disconnected from a sexual identity they held in their 30s. This responds to different interventions than hormonal ones.

Communication about change. Couples who openly discuss what is happening in perimenopause (pain, less lubrication, the need for different or longer foreplay) adapt more successfully than those who do not. Silence lets both partners build unhelpful stories: one concludes they are no longer attracted to their partner; the other concludes their partner has lost interest in them.

Hormonal Factors

Testosterone. There is solid evidence that transdermal testosterone at physiological female doses improves sexual desire, arousal, and satisfaction in postmenopausal women with hypoactive sexual desire disorder (HSDD). The evidence is specific to HSDD (defined as distressing low desire) and to the postmenopausal context.

Testosterone is not appropriate or effective for low desire driven by pain, relationship difficulty, depression, or sleep deprivation. The ISSWSH guideline recommends it after other causes have been assessed.[3]

Estrogen via HRT. Systemic HRT does not directly increase sexual desire or improve orgasm, but its indirect effects can be significant. HRT improves sleep, reduces hot flashes, steadies mood, and at systemic doses can improve genitourinary symptoms. Women who start HRT for hot flashes or sleep often report a secondary improvement in sexual wellbeing as quality of life improves.

Local vaginal estrogen. For women whose reduced desire is driven mainly by GSM-related painful sex, local estrogen is often the most targeted and effective step. It does not raise desire through a hormonal mechanism. It removes the physical barrier that was suppressing desire.

A Clinical Framework for Treatment

Because reduced desire in midlife has several causes, treatment works best when it identifies the specific contributors rather than defaulting to one intervention.

  1. Is there pain during sex? If yes, address GSM first. Local estrogen, vaginal moisturizers, or ospemifene, depending on history and preference.

  2. Is sleep severely disrupted? If yes, treating the sleep disruption is more likely to restore libido than any direct sexual intervention.

  3. Is significant depression or anxiety present? If yes, treating the mood disorder takes priority.

  4. Are relationship factors dominant? If yes, couples communication, psychosexual counselling, or therapy is more useful than hormonal treatment.

  5. Is desire reduced despite adequate sleep, no pain, no significant mood disorder, and a supportive relationship? This is the profile for which testosterone has the strongest evidence.

Women who get accurate guidance about which physical factors are treatable report significantly better sexual wellbeing than those who get no information or who are told that reduced desire is simply a normal part of aging.[2]


References

[1] Simon, J. A., Nappi, R. E., Kingsberg, S. A., Maamari, R., Brown, V. (2014). Clarifying vaginal atrophy’s impact on sex and relationships. Menopause, 21(2), 137-142. See also: Management of libido problems in menopause. https://pmc.ncbi.nlm.nih.gov/articles/PMC6220606/

[2] O’Sullivan, A. J., et al. (2024). Women’s experiences of intimate and sexual relationships during menopause: a qualitative synthesis. Menopause, 31(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC12037939/

[3] Parish, S. J., Simon, J. A., Davis, S. R., et al. (2021). International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. Journal of Sexual Medicine, 18(5), 849-867. https://pubmed.ncbi.nlm.nih.gov/33797277/

Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.